PMID: 15338802Sep 2, 2004Paper

Resource use and risk factors in high-cost exacerbations of COPD

Respiratory Medicine
Jan B Oostenbrink, M P Rutten-van Mölken

Abstract

Patients hospitalised for exacerbations contribute significantly to the total chronic obstructive pulmonary disease (COPD)-related healthcare costs. This study aimed to determine the resource use and costs of exacerbations by exacerbation-severity and to identify risk factors for hospitalisation. Exacerbations and the details of all associated healthcare utilisation were recorded as part of a prospective cost-effectiveness analysis linked to two randomised controlled trials comparing tiotropium with ipratropium in 519 patients with stable COPD at study entry in the Netherlands and Belgium. Exacerbation-severity was rated by the physician. A Cox proportional hazards analysis was performed to identify independent risk factors of hospitalisation. Covariates that entered this analysis were smoking status, pack-years, body mass index, number of concomitant diseases, number of concomitant medications, use of inhaled steroids, physician visits prior to trial, FEV1% predicted, quality of life, baseline dyspnea index (BDI) and treatment arm. The mean number of exacerbations per patient was 0.70 (95%-CI:0.60, 0.81). About 10% of the exacerbations was severe, 47% moderate and 43% was mild. The mean costs of these exacerbations were Euro 4...Continue Reading

References

Feb 1, 1987·Annals of Internal Medicine·N R AnthonisenN A Nelson
Feb 16, 2000·Chest·S D SullivanT A Lee
May 12, 2000·American Journal of Respiratory and Critical Care Medicine·T A SeemungalJ A Wedzicha
Nov 18, 2000·Chest·D E HillemanM Friedman
Aug 25, 2001·American Journal of Respiratory and Critical Care Medicine·T L FeenstraM P Rutten-van Mölken
May 15, 2002·Chest·Marc MiravitllesUNKNOWN DAFNE Study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC
Sep 24, 2002·Respiratory Medicine·F AnderssonB Lundbäck
Feb 26, 2004·The European Respiratory Journal·J B OostenbrinkW Vincken

❮ Previous
Next ❯

Citations

Feb 9, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Yevgeniy SamyshkinEric D Bateman
May 12, 2006·Respiratory Research·Luigi G FranciosiOscar E Della Pasqua
Nov 30, 2007·International Journal of Chronic Obstructive Pulmonary Disease·Anna M SadowskaW A De Backer
Dec 1, 2007·International Journal of Chronic Obstructive Pulmonary Disease·Tom Wilkinson, J A Wedzicha
Dec 31, 2010·International Journal of Chronic Obstructive Pulmonary Disease·Martine HoogendoornMaureen Rutten-van Mölken
Apr 20, 2011·Journal of Medical Economics·Andrew P YuSteven Blum
Oct 26, 2013·Current Medical Research and Opinion·Jian LinJiaxi Feng
Jul 28, 2006·Current Medical Research and Opinion·Nikos ManiadakisNikolaos Siafakas
Apr 26, 2011·COPD·Kathryn GaebelRon Goeree
Sep 4, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Lilian H F HoonhoutMaurits W van Tulder
Nov 21, 2009·The American Journal of the Medical Sciences·Márcia Maria FaganelloIrma Godoy
Jan 17, 2008·Chest·Karin H GroenewegenUNKNOWN COSMIC Study Group
Feb 8, 2011·Journal of Health Economics·Claudine de MeijerEddy van Doorslaer
Aug 17, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Martine HoogendoornMaureen P M H Rutten-van Mölken
Aug 17, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Lucas M A GoossensMaureen P M H Rutten-van Mölken
Feb 1, 2007·International Journal of Clinical Practice·S SimoensG Laekeman
Oct 2, 2009·Journal of Thrombosis and Haemostasis : JTH·A J Ten Cate-HoekM A Joore
Nov 5, 2015·Journal of Medical Economics·Thomas R EinarsonMichiel E H Hemels
Mar 23, 2007·Expert Opinion on Pharmacotherapy·Steven Simoens, Marc Decramer
May 3, 2006·Respiratory Medicine·Steven SimoensGert Laekeman
Apr 22, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jan B OostenbrinkJ Mark FitzGerald
Dec 14, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Martine HoogendoornTalitha L Feenstra
Apr 9, 2015·Frontiers in Public Health·Vojislav Cupurdija
Nov 3, 2010·Respiratory Medicine·Sevim BavbekUNKNOWN ADVISE Study Group
Aug 8, 2007·Respiratory Medicine·Daniela KolevaUNKNOWN Study Group BIC
Oct 26, 2010·Respiratory Medicine·Mary GeitonaDemosthenes Bouros
Oct 13, 2012·Respiratory Medicine·Cayo García-PoloUNKNOWN InEPOC Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Jan B OostenbrinkJ Mark FitzGerald
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Sixten BorgS D Sullivan
American Journal of Respiratory and Critical Care Medicine
T A R SeemungalJ A Wedzicha
© 2021 Meta ULC. All rights reserved